RFA, embolization protocol safely treats large fibroids

Article

Reducing fibroid volume with radiofrequency ablation and then embolizing the fibroids is safe and feasible, according to a study presented at the 2005 RSNA meeting.

Reducing fibroid volume with radiofrequency ablation and then embolizing the fibroids is safe and feasible, according to a study presented at the 2005 RSNA meeting.

Dr. Hyun Kim and Jason Tsai of Johns Hopkins treated 22 symptomatic patients with large subserosal fibroids with RFA and uterine fibroid embolization. They used an RF probe up to 5 cm.

They achieved RFA target ablation size and temperature in 95.5% (21/22) of patients. A mean fibroid volume reduction of 49% was achieved (549 cc pretreatment versus 280.8 cc post-treatment). After one day, an MR scan in 10 patients showed no extra-uterine organ damage, as well as no infection, hemorrhagic complication, or fluid in pelvis or peritoneum. One patient developed delayed minimal drainage via RFA probe skin access, which resolved spontaneously over two days.

Follow-up at one year has revealed no significant morbidity, positive symptom severity scores, and few complications.

Recent Videos
Study: MRI-Based AI Enhances Detection of Seminal Vesicle Invasion in Prostate Cancer
What New Research Reveals About the Impact of AI and DBT Screening: An Interview with Manisha Bahl, MD
Can AI Assessment of Longitudinal MRI Scans Improve Prediction for Pediatric Glioma Recurrence?
A Closer Look at MRI-Guided Adaptive Radiotherapy for Monitoring and Treating Glioblastomas
Incorporating CT Colonography into Radiology Practice
What New Research Reveals About Computed Tomography and Radiation-Induced Cancer Risk
What New Interventional Radiology Research Reveals About Treatment for Breast Cancer Liver Metastases
New Mammography Studies Assess Image-Based AI Risk Models and Breast Arterial Calcification Detection
Can Deep Learning Provide a CT-Less Alternative for Attenuation Compensation with SPECT MPI?
Employing AI in Detecting Subdural Hematomas on Head CTs: An Interview with Jeremy Heit, MD, PhD
Related Content
© 2025 MJH Life Sciences

All rights reserved.